Jingye Zhou, Eccogene CEO
AstraZeneca puts down $185M upfront for PhI oral GLP-1 as it shoots for next-gen win
AstraZeneca has recruited a new star to its budding GLP-1 show, picking up an early-stage oral candidate from China’s Eccogene in a deal featuring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.